文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于砹-211的放射性核素治疗：当前临床试验概况。

Astatine-211 based radionuclide therapy: Current clinical trial landscape.

作者信息

Albertsson Per, Bäck Tom, Bergmark Karin, Hallqvist Andreas, Johansson Mia, Aneheim Emma, Lindegren Sture, Timperanza Chiara, Smerud Knut, Palm Stig

机构信息

Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

出版信息

Front Med (Lausanne). 2023 Jan 6;9:1076210. doi: 10.3389/fmed.2022.1076210. eCollection 2022.

DOI:10.3389/fmed.2022.1076210
PMID:36687417
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9859440/
Abstract

Astatine-211 (At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.

摘要

砹 - 211（At）具有的物理性质使其成为基于α粒子的放射性核素治疗（也称为靶向α治疗，TAT）辐射源的最佳候选者之一。在此，我们总结已完成临床试验的主要结果，进一步描述正在进行的试验，并讨论未来前景。

相似文献

[1]
Astatine-211 based radionuclide therapy: Current clinical trial landscape.

Front Med (Lausanne). 2023-1-6

[2]
Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.

Pharmaceutics. 2020-12-31

[3]
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.

Expert Opin Biol Ther. 2016-5-19

[4]
Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.

Eur J Nucl Med Mol Imaging. 2020-1

[5]
Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.

Sci Rep. 2015-7-14

[6]
Targeted alpha therapy: part I.

Curr Radiopharm. 2011-7

[7]
Targeted cancer cell ablation in mice by an α-particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B.

Biochem Biophys Res Commun. 2018-11-5

[8]
Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.

Med Phys. 2015-7

[9]
The in vitro radiobiology of astatine-211 decay.

Radiat Res. 1986-1

[10]
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.

Curr Radiopharm. 2011-10

引用本文的文献

[1]
Biodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225/Francium-221 radionuclide generator Set-up.

Eur J Nucl Med Mol Imaging. 2025-7-1

[2]
Copper-mediated radiochemistry: historical impact, current trends, and future possibilities.

Npj Imaging. 2025-6-10

[3]
Locoregional radionuclide therapy of glioblastoma with [At]At-PDA-FAPI.

Sci Rep. 2025-5-25

[4]
Ortho-functionalization of a At-labeled aryl compound provides stabilization of the C-At bond against oxidative dehalogenation.

Sci Rep. 2025-5-15

[5]
Enhancing the Stability of At Radiopharmaceuticals: Insights from Ortho-Substituent Strategies.

ACS Med Chem Lett. 2025-3-20

[6]
Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care.

Cancers (Basel). 2025-3-31

[7]
The Advancement of Targeted Alpha Therapy and the Role of Click Chemistry Therein.

Molecules. 2025-3-13

[8]
Preclinical investigation of [Tb]Tb-DOTATATE and [Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy.

Eur J Nucl Med Mol Imaging. 2025-3

[9]
Enhancing the radionuclide theranostic concept through the radiohybrid approach.

RSC Med Chem. 2024-11-25

[10]
Nanoscale Radiotheranostics for Cancer Treatment: From Bench to Bedside.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024

本文引用的文献

[1]
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma.

Commun Biol. 2022-11-17

[2]
Pretargeting: A Path Forward for Radioimmunotherapy.

J Nucl Med. 2022-9

[3]
The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials.

Updates Surg. 2022-12

[4]
Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Cancers (Basel). 2022-8-28

[5]
Targeted Alpha Therapy of Glioma Using At-Labeled Heterodimeric Peptide Targeting Both VEGFR and Integrins.

Mol Pharm. 2022-9-5

[6]
Individualization of Radionuclide Therapies: Challenges and Prospects.

Cancers (Basel). 2022-7-14

[7]
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.

Clin Cancer Res. 2022-9-15

[8]
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with At Intraperitoneal Radioimmunotherapy.

J Nucl Med. 2023-1

[9]
Manual on the proper use of meta-[At] astato-benzylguanidine ([At] MABG) injections in clinical trials for targeted alpha therapy (1st edition).

Ann Nucl Med. 2022-8

[10]
Radiotheranostics in oncology: current challenges and emerging opportunities.

Nat Rev Clin Oncol. 2022-8

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索